The latest 510(k) clearance for the Verily Study Watch will further the efforts of the Google sister company and iRhythm Technologies (NSDQ:IRTC) to improve atrial fibrillation treatment. Verily — a life science company under Alphabet (NSDQ:GOOGL) — recently received an FDA 510(k) clearance to include an irregular pulse monitor in its Study Watch wearable. “We’ve worked carefully […]
iRhythm releases delayed Q3 earnings report, falls short of Street projections
iRhythm Technologies (NSDQ:IRTC) shares are slightly up today on third-quarter results that came up short of the consensus forecast. The San Francisco-based company delayed its third-quarter report in November due to a previously disclosed material weaknesses. At the time, the company said it identified errors that affected prior periods while preparing the quarterly report for the […]
iRhythm touts AFib study
iRhythm Technologies (NSDQ:IRTC) announced that it is participating in a new Bristol-Myers Squibb–Pfizer (NYSE:PFE) Alliance study for reducing stroke by screening for undiagnosed atrial fibrillation in elderly individuals. The goal of the “Guard-AF” study is to determine if earlier detection of AFib can impact the rate of stroke through screening previously undiagnosed people who are at least […]
iRhythm Technologies won’t file 10-Q, citing material weaknesses
iRhythm Technologies (NSDQ:IRTC) this week said it would not be filing its quarterly report on Form 10-Q, citing previously disclosed material weaknesses, according to an SEC filing. The San Francisco-based company said it identified errors that affected prior periods while preparing the quarterly report for the period ended Sept. 30, 2019. The errors could affect the […]
iRhythm closes $115m offering
iRhythm Technologies (NSDQ:IRTC) said yesterday that it closed its underwritten public offering of common stock for gross proceeds exceeding $100 million. The San Fransisco-based company said it offered nearly 1.6 million shares at $73 per share, including the exercise in full of the underwriters’ option to purchase an additional 205,479 shares. iRhythm initially estimated net proceeds […]
iRhythm prices $100m offering
iRhythm Technologies (NSDQ:IRTC) yesterday priced a stock offering worth at least $100 million it plans to use in part to fund a co-development deal with Alphabet (NSDQ:GOOGL) life sciences unit Verily. The 1.37-million-share flotation includes a 30-day underwriters option on another 205,000 shares that would add $15 million if exercised in full. The offering is slated to close […]
iRhythm unveils $13m Verily afib deal, readies $100m offering
iRhythm Technologies (NSDQ:IRTC) said yesterday that it inked a deal worth nearly $13 million with Alphabet (NSDQ:GOOGL) life sciences unit Verily to develop AI-based screening, diagnosis and management technology for atrial fibrillation and said it’s readying a stock offering worth $100 million in part to back the collaboration. The deal to integrate Verily’s data analytics into […]
iRhythm rises on Q1 beats, raised sales outlook
iRhythm Technologies (NSDQ:IRTC) posted a classic beat-and-raise first quarter yesterday, topping the consensus forecasts on Wall Street and boosting its top-line outlook on the rest of the year. The San Francisco-based wearable heart monitor maker cut its losses by -27.9% to -$8.0 million, or -33¢ per share, on sales growth of 54.5% to $47.2 million […]
NIH director Collins touts AF detection capabilities of iRhythm’s Zio ECG patch
iRhythm Technologies‘ Zio ECG patch won praises from NIH Director Dr. Francis Collins this week for its ability to aid in the detection of atrial fibrillation. In an NIH Director blog post, Dr. Collins warned that while the dangers of atrial fibrillation are known, many individuals do not know they have atrial fibrillation and therefore […]
NinePoint Medical lifts Namati to the corner office | Personnel Moves – July 10, 2018
NinePoint Medical said earlier this month that it appointed Eman Namati as its new president and chief executive officer, succeeding Christopher von Jako who will remain on the company’s board of directors. Namati joined NinePoint Medical at its inception in 2010 as a technical co-founder, and operated as R&D VP for the past four years, […]
ACC ’18 Roundup: Abbott releases long-term HeartMate 3 data
Abbott (NYSE:ABT) touted two-year data yesterday from its trial designed to compare the company’s HeartMate 3 left ventricular assist device to its HeartMate 2 device in patients with advanced heart failure. Data from the study were published in The New England Journal of Medicine and presented at the American College of Cardiology’s 67th Annual Scientific Session. More […]
MassDevice Network
@MassDevice
LinkedIn
YouTube